DELOS Desarrollo Local Sostenible
December 11, 2025
Pedro Rodrigues, Weliton Rodrigues Dos Santos Júnior, Ivan de Sousa Araújo et al.
Objective: To compare acceptability and effectiveness of psilocybin, ketamine and commonly prescribed antidepressants in the management of Major Depressive Disorder (MDD). Methods: This is a systematic review with network meta-analysis. The survey was conducted between January and June 2023, employing MEDLINE, PsyINFO, Embase, Web of Science and ClinicalTrials.gov databases. Randomized...
December 10, 2025
Johannes Jungwirth, Samuel Westenhöfer, Helena Aicher et al.
preprint
Abstract Psilocybin has demonstrated promising antidepressant effects in depression and treatment-resistant depression (TRD) in controlled clinical trials. However, its effectiveness and safety in real-world therapeutic settings remain largely unknown. Although psilocybin is not yet approved as an antidepressant treatment, Switzerland’s unique legal framework allows its limited medical use for...
Journal of Eating Disorders
December 9, 2025
Elizabeth Wassenaar, Dan V. Blalock, Alan Duffy et al.
1 citation
Individuals with eating disorders (EDs) have an increased risk of treatment resistant depression (TRD) and treatment resistant bipolar disorder (TRBD) and a higher rate of suicidal ideation and death by suicide than individuals without EDs. Individuals with EDs are less responsive to conventional treatments for mood disorders than individuals without EDs. Ketamine has evidence for treatment of...
General Hospital Psychiatry
December 9, 2025
Gerasimos Konstantinou, Joshua D. Rosenblat, Sarah Hales et al.
4 citations
The global demographic shift toward aging populations has intensified the need for innovative therapeutic interventions targeting late-life mental health conditions, notably depression, loneliness, and existential distress. Traditional pharmacological treatments often exhibit limited efficacy and poor tolerability in older patients, primarily due to age-related physiological changes and the...
NPJ Digital Medicine
December 8, 2025
Joseph Geraci, Bessi Qorri, Mike Tsay et al.
Clinical trial failures are frequently driven by patient heterogeneity and limited sample sizes that obscure treatment effects by diluting statistical power. We introduce NetraAI, a novel explainable artificial intelligence (AI) platform that integrates dynamical-systems modeling, evolutionary long-range memory feature selection, and large-language model (LLM)-generated insights, to discover...
BMJ Open
December 8, 2025
Thorsten Barnhofer, Maria Niemi, Johannes Michalak et al.
Introduction: About 30% of depressed patients suffer from a protracted course in which the disorder continues to cause significant burden despite treatment efforts. While originally developed for relapse prevention, mindfulness-based cognitive therapy (MBCT) has increasingly been investigated in depressed patients with such 'difficult-to-treat' courses. This is a protocol for an individual...
Journal of Pharma Insights and Research
December 5, 2025
Syed Ansar, S. Ahmed, Aishvarya Baburao Ghayale et al.
Major Depressive Disorder (MDD), particularly its treatment-resistant form, represents a substantial burden on global public health, characterized by low remission rates with conventional monoaminergic pharmacotherapy. The paradigm shift toward glutamatergic modulation has identified the N-methyl-D-aspartate (NMDA) receptor as a critical target for rapid-acting antidepressants. Nitrous oxide...
Journal of Cultural Analysis and Social Change
December 4, 2025
Eppy Setiyowati, Nur Hidaayah, Mulyadi Mulyadi et al.
In general, ischemic stroke patients experience psychological problems anxiety, depression and increased blood pressure to be above normal. The purpose of the study was to analyze anxiety, depression and blood pressure post mindfulness spiritual intervention combination breathing exercise. Quasy experiment research design with a large sample of 25 respondents through purposive sampling...
Frontiers in Psychiatry
December 4, 2025
Adam Włodarczyk, Jakub Słupski, Joanna Szarmach et al.
Ketamine may be a viable treatment option for patients with treatment-resistant post-stroke depression. Further research is warranted to better understand the efficacy and safety of ketamine in this specific patient population.
Therapeutic Advances in Psychopharmacology
December 4, 2025
Carina Joy Donegan, Dimitri Daldegan-Bueno, Rachael Sumner et al.
Background: Depressive disorders affect approximately 280 million globally, with many finding treatments ineffective or limited by side effects. Growing evidence suggests that psychedelic therapies may help alleviate depressive symptoms. Among these, lysergic acid diethylamide (LSD) microdosing shows promise for major depressive disorder (MDD). However, research on LSD microdosing in clinical...